Please Wait...

Thomas Fuerst

Translation skills

Main profile

Thomas Fuerst, Ph.D.
Chief Science Officer Head of Musculoskeletal

Dr. Thomas Fuerst leads the design and scientific oversight of musculoskeletal clinical trials for Bioclinica. Dr. Fuerst received his Ph.D. in medical physics from the University of Wisconsin at Madison and has more than 13 years of research experience in bone densitometry, vertebral fracture methods and body composition assessment with a focus on multicenter clinical trials. Prior to joining Bioclinica, he was a faculty member of the University of California, San Francisco, where he served as Director of the Quality Assurance Center and as Associate Director of the Osteoporosis and Arthritis Research Group (OARG). While at UCSF, he successfully coordinated the collection, quality control and centralized analysis of densitometry scans and imaging data for international, multi-center Phase II and Phase III clinical trials. Dr. Fuerst is also the co-founder of the imaging core lab Synarc, where he served as Scientific Director.

As an active member of the International Committee for Standards in Bone Measurement, Dr. Fuerst has worked to improve, standardize, and advance bone density technologies. He routinely consults with industry and government agencies on the use of DXA to evaluate bone mineral density and body composition.

Authored Publications

Mark Tengowski, DVM, PhD, Scientific Director, Bioclinica; Thomas Fuerst, PhD, Chief Science Officer, Bioclinica, and Claude B Sirlin, UC San Diego Medical Center and UC San Diego Liver Imaging Group. Magnetic resonance imaging fatty liver changes following surgical, lifestyle or drug treatments in obese, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis subjects. Journal of Imaging Medicine, September 2017.

Philip G Conaghan, Mikkel Østergaard, Michael A Bowes, Chunying Wu, Thomas Fuerst, Désirée van der Heijde, Fedra Irazoque-Palazuelos, Oscar Soto-Raices, Pawel Hrycaj, Zhiyong Xie, Richard Zhang, Bradley T Wyman, John D Bradley, Koshika Soma, Bethanie Wilkinson.  Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques.  Ann Rheum Dis.  25 January 2016.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

RT @MdFacep: FDA approvals: Merck's Keytruda wins FDA approval as combination therapy for kidney cancer. BIG! https://t.co/LgCzL1mvaF @Reu…
Bioclinica (8 hours ago)
RT @FDA_Drug_Info: National Prescription Drug Take Back Day is April 27, 2019 from 10:00 AM to 2:00 PM. Learn how to dispose of unused and…
Bioclinica (8 hours ago)
RT @iofbonehealth: #Osteoporosis Int: Spanish National Hip Fracture Registry (RNFC): analysis of its first annual report and international…
Bioclinica (8 hours ago)
RT @HINJ_ORG: New Jersey's biopharmaceutical industry: CIANJ has assembled a panel of industry leaders @Celgene, @Bayer & @PhRMA to discuss…
Bioclinica (8 hours ago)
RT @PhRMA: Last year, the top 15 largest biopharmaceutical companies spent more than $100 billion on R&D, according to @IQVIA_global. More…
Bioclinica (8 hours ago)
RT @SCDM_DataDriven: Registrations for the SCDM 2019 Annual Conference are now open!! #SCDM2019 Register now for the biggest event in the…
Bioclinica (8 hours ago)

Latest Blogs:

Site Payments Solutions
Nonalcoholic steatohepatitis (NASH) development programs
Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box